CN101052655A - 用于治疗乳腺癌的ctla4抗体和芳香酶抑制剂组合物 - Google Patents

用于治疗乳腺癌的ctla4抗体和芳香酶抑制剂组合物 Download PDF

Info

Publication number
CN101052655A
CN101052655A CNA2005800377929A CN200580037792A CN101052655A CN 101052655 A CN101052655 A CN 101052655A CN A2005800377929 A CNA2005800377929 A CN A2005800377929A CN 200580037792 A CN200580037792 A CN 200580037792A CN 101052655 A CN101052655 A CN 101052655A
Authority
CN
China
Prior art keywords
antibody
ser
seq
val
thr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2005800377929A
Other languages
English (en)
Chinese (zh)
Inventor
J·戈麦斯-纳瓦罗
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Products Inc
Original Assignee
Pfizer Products Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc filed Critical Pfizer Products Inc
Publication of CN101052655A publication Critical patent/CN101052655A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
CNA2005800377929A 2004-11-04 2005-10-24 用于治疗乳腺癌的ctla4抗体和芳香酶抑制剂组合物 Pending CN101052655A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62485604P 2004-11-04 2004-11-04
US60/624,856 2004-11-04

Publications (1)

Publication Number Publication Date
CN101052655A true CN101052655A (zh) 2007-10-10

Family

ID=35825412

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2005800377929A Pending CN101052655A (zh) 2004-11-04 2005-10-24 用于治疗乳腺癌的ctla4抗体和芳香酶抑制剂组合物

Country Status (15)

Country Link
EP (1) EP1819735A1 (fr)
JP (1) JP2008518902A (fr)
KR (1) KR20070067702A (fr)
CN (1) CN101052655A (fr)
AR (1) AR053651A1 (fr)
AU (1) AU2005300315A1 (fr)
BR (1) BRPI0515735A2 (fr)
CA (1) CA2586844A1 (fr)
IL (1) IL182244A0 (fr)
MX (1) MX2007003804A (fr)
NO (1) NO20072576L (fr)
RU (1) RU2007114111A (fr)
TW (1) TW200621804A (fr)
WO (1) WO2006048749A1 (fr)
ZA (1) ZA200702577B (fr)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102822200A (zh) * 2009-07-20 2012-12-12 百时美施贵宝公司 对增殖性疾病进行协同性治疗的抗ctla-4抗体与各种治疗方案的组合
CN103768596A (zh) * 2012-10-17 2014-05-07 傅阳心 用于肿瘤治疗的组合产品、其用途及相关方法
CN105636986A (zh) * 2013-10-18 2016-06-01 瑞泽恩制药公司 包含vegf拮抗剂和抗-ctla-4抗体的组合的方法和组合物
WO2017101863A1 (fr) * 2015-12-16 2017-06-22 上海康岱生物医药技术股份有限公司 Anticorps conjugué bispécifique, procédé de préparation s'y rapportant et son utilisation
CN109906088A (zh) * 2016-08-26 2019-06-18 奥野哲治 微血管血流减少剂及其应用

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2605796A1 (fr) * 2005-04-25 2006-11-02 Pfizer Products Inc. Compositions pharmaceutiques et methodes comprenant une combinaison d'un modulateur selectif du recepteur de l'oestrogene et d'un inhibiteur de l'aromatase
SG163583A1 (en) * 2005-07-07 2010-08-30 Coley Pharm Group Inc Anti-ctla-4 antibody and cpg-motif-containing synthetic oligodeoxynucleotide combination therapy for cancer treatment
US7700567B2 (en) 2005-09-29 2010-04-20 Supergen, Inc. Oligonucleotide analogues incorporating 5-aza-cytosine therein
CA2647282A1 (fr) * 2006-04-05 2007-10-11 Pfizer Products Inc. Polytherapie a base d'un anticorps anti-ctla4
CN101909693A (zh) * 2008-01-08 2010-12-08 百时美施贵宝公司 用于治疗增殖性疾病的抗-ctla4抗体与微管蛋白调节剂的组合
WO2010014784A2 (fr) * 2008-08-01 2010-02-04 Bristol-Myers Squibb Company Combinaison d'anticorps anti-ctla4 avec divers régimes thérapeutiques pour un traitement synergétique de maladies prolifératives
US8829173B2 (en) 2008-09-26 2014-09-09 Tocagen Inc. Recombinant vectors
EA027693B1 (ru) 2008-09-26 2017-08-31 Токаджен Инк. Рекомбинантный репликационно-компетентный ретровирус с цитозиндезаминазной активностью для генной терапии нарушений клеточной пролиферации
WO2010040105A2 (fr) 2008-10-02 2010-04-08 Trubion Pharmaceuticals, Inc. Protéines de liaison multicibles antagonistes de cd86
EP2710137B1 (fr) 2011-03-10 2018-09-19 Provectus Pharmatech, Inc. Une combinaison de rose bengale et un antikorps anti-ctla4 pour le traitement du cancer
KR102004559B1 (ko) 2011-08-30 2019-07-26 아스텍스 파마수티컬스, 인크. 데시타빈 유도체 제제
HUE044352T2 (hu) * 2011-10-14 2019-10-28 Hoffmann La Roche Pertuzumab, Trastuzumab, Docetaxel és Carboplatin korai stádiumú mellrák kezelésére
PE20142406A1 (es) 2012-05-04 2015-01-23 Pfizer Antigenos asociados a prostata y regimenes de inmunoterapia basados en vacuna
CN104884627A (zh) 2012-10-25 2015-09-02 托卡根公司 具有小型启动子盒的逆转录病毒载体
CN110448566A (zh) 2013-03-01 2019-11-15 阿斯泰克斯制药公司 药物组合
JP6768722B2 (ja) 2015-07-02 2020-10-14 大塚製薬株式会社 凍結乾燥医薬組成物
EA201890640A1 (ru) 2015-09-04 2018-09-28 Токаджен Инк. Рекомбинантные векторы, содержащие пептид 2а
SG11201805835WA (en) 2016-01-08 2018-08-30 Replimune Ltd Modified oncolytic virus
US11542332B2 (en) 2016-03-26 2023-01-03 Bioatla, Inc. Anti-CTLA4 antibodies, antibody fragments, their immunoconjugates and uses thereof
JP7461741B2 (ja) 2016-06-20 2024-04-04 カイマブ・リミテッド 抗ｐｄ－ｌ１およびｉｌ－２サイトカイン
WO2018098352A2 (fr) 2016-11-22 2018-05-31 Jun Oishi Ciblage d'expression du point de contrôle immunitaire induit par kras
HUE064898T2 (hu) 2017-03-02 2024-04-28 Genentech Inc HER2-pozitív emlõrák adjuváns kezelése
WO2018167780A1 (fr) * 2017-03-12 2018-09-20 Yeda Research And Development Co. Ltd. Méthodes de diagnostic et de traitement du cancer
BR112020002280A2 (pt) 2017-08-03 2020-07-28 Otsuka Pharmaceutical Co., Ltd. composto farmacológico e métodos purificação do mesmo
WO2021173870A1 (fr) * 2020-02-27 2021-09-02 University Of Washington Composition et procédé pour préparer une suspension injectable à action prolongée contenant de multiples médicaments anticancéreux

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL149701A0 (en) * 2001-05-23 2002-11-10 Pfizer Prod Inc Use of anti-ctla-4 antibodies

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102822200A (zh) * 2009-07-20 2012-12-12 百时美施贵宝公司 对增殖性疾病进行协同性治疗的抗ctla-4抗体与各种治疗方案的组合
CN103768596A (zh) * 2012-10-17 2014-05-07 傅阳心 用于肿瘤治疗的组合产品、其用途及相关方法
CN103768596B (zh) * 2012-10-17 2016-06-22 苏州丁孚靶点生物技术有限公司 用于肿瘤治疗的组合产品、其用途及相关方法
CN105636986A (zh) * 2013-10-18 2016-06-01 瑞泽恩制药公司 包含vegf拮抗剂和抗-ctla-4抗体的组合的方法和组合物
CN105636986B (zh) * 2013-10-18 2020-05-12 瑞泽恩制药公司 包含vegf拮抗剂和抗-ctla-4抗体的组合的方法和组合物
WO2017101863A1 (fr) * 2015-12-16 2017-06-22 上海康岱生物医药技术股份有限公司 Anticorps conjugué bispécifique, procédé de préparation s'y rapportant et son utilisation
US11021538B2 (en) 2015-12-16 2021-06-01 Shanghai Kanda Biotechnology Co, Ltd Bispecific coupled antibody, preparation method and application thereof
CN109906088A (zh) * 2016-08-26 2019-06-18 奥野哲治 微血管血流减少剂及其应用

Also Published As

Publication number Publication date
TW200621804A (en) 2006-07-01
MX2007003804A (es) 2007-04-23
AR053651A1 (es) 2007-05-16
ZA200702577B (en) 2008-07-30
IL182244A0 (en) 2007-09-20
CA2586844A1 (fr) 2006-05-11
RU2007114111A (ru) 2008-12-10
NO20072576L (no) 2007-08-03
WO2006048749A1 (fr) 2006-05-11
KR20070067702A (ko) 2007-06-28
BRPI0515735A2 (pt) 2011-10-11
JP2008518902A (ja) 2008-06-05
AU2005300315A1 (en) 2006-05-11
EP1819735A1 (fr) 2007-08-22

Similar Documents

Publication Publication Date Title
CN101052655A (zh) 用于治疗乳腺癌的ctla4抗体和芳香酶抑制剂组合物
KR102493282B1 (ko) Tim3에 대한 항체 및 그의 용도
KR20070104673A (ko) 암의 치료를 위한 항－ｃｔｌａ４ 항체와 인돌리논병용요법
JP6313825B2 (ja) 癌の治療のための抗−４−１ｂｂ抗体及びａｄｃｃ誘導抗体の組合せ
KR100531707B1 (ko) 항-ｃｔｌａ-4 항체의 용도
KR20070108259A (ko) Ｃｔｌａ-4 항체와 호르몬 요법에 의한 전립선암의 치료법
KR101340699B1 (ko) 인간 모노클로날 항체 인간 ｃｄ１３４（ｏｘ４０） 및이의 제조 및 사용 방법
CN101268101A (zh) 用于癌症治疗的抗-CTLA-4抗体和含有CpG基序的合成寡脱氧核苷酸联合治疗
CN1863817A (zh) M－csf的抗体
CN110914299A (zh) 抗icos促效剂抗体和其用途
CA2647282A1 (fr) Polytherapie a base d'un anticorps anti-ctla4
TW200829271A (en) Uses of anti-CTLA-4 antibodies
CN1835975A (zh) 经修饰的人类igf－1r抗体
EA032830B1 (ru) Антитела к pac1 человека и их применение для лечения головной боли
KR20200135830A (ko) Mica 및/또는 micb에 대한 항체 및 그의 용도
KR20200044899A (ko) 암의 치료 및 진단을 위한 tim-3 길항제
KR20200109339A (ko) Tim3에 대한 항체를 사용하여 암을 치료하는 방법
KR20200108870A (ko) Tim3에 대한 항체 및 그의 용도
NZ789986A (en) Antibodies against tim3 and uses thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1114103

Country of ref document: HK

C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Open date: 20071010

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1114103

Country of ref document: HK